In CTCL, PD-1 and its ligands can be simultaneously expressed on tumor cells, making this pathway an attractive therapeutic target for PD-1 blockade9–12. This evidence concerns the gene PDCD1 and primary cutaneous T-cell non-Hodgkin lymphoma.